Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation

Launched by YULAN REN · Nov 1, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to detect endometrial cancer early, which is a type of cancer that affects the lining of the uterus. The researchers want to see how well two non-invasive tests—liquid-based cytology (a method that examines cells from the uterus) and cervical methylation testing (which checks for specific changes in DNA)—can identify cancer compared to traditional methods that involve taking tissue samples. They hope that these tests will not only help in early detection but also be useful in evaluating treatments that aim to preserve fertility for women diagnosed with endometrial cancer.

To participate in the study, women must have certain conditions, such as having abnormal growths in the uterus or being evaluated for treatments that allow them to maintain their ability to have children. Participants will need to provide informed consent and should be in good health overall. If you’re interested in joining, it’s important to know that you cannot have certain conditions like cervical cancer or be pregnant. The study is not yet recruiting participants, but it aims to provide valuable information that could improve both cancer screening and fertility preservation options for women in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Participants must meet all of the following criteria to be eligible for the study:
• • 1. Color Doppler ultrasound indicating intrauterine masses or abnormal endometrial thickening (for postmenopausal women not receiving hormone replacement therapy, endometrial thickness \>5mm).
• • 2. Patients undergoing follow-up and efficacy evaluation for fertility-sparing treatment of endometrial cancer or atypical endometrial hyperplasia.
• • 3. Patients with endometrial thickening following endocrine therapy for breast cancer.
• • 4. Signed informed consent form.
• • 5. Good compliance.
• Exclusion Criteria:
• * Participants meeting any of the following criteria will be excluded:
• • 1. Diagnosed with cervical cancer.
• • 2. Severe systemic complications preventing hysteroscopy.
• • 3. Pregnant or recent history of miscarriage.
• • 4. Acute genital tract infection or pelvic inflammatory disease.
• • 5. Insertion of an intrauterine device.
• • 6. Sexual activity, vaginal douching, or medication use within 24 hours.